#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Lymphoma Mucopolysaccharidosis III Cystic fibrosis Bronchopulmonary dysplasia Uveitis Antiphospholipid antibodies Familial dilated cardiomyopathy Non-Hodgkin's lymphoma Anti-myelin-associated glycoprotein antibodies positive Bladder cancer Angiosarcoma metastatic Spinal cord injury Adenovirus infection Phaeochromocytoma Extraskeletal ossification More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis III – Life with Disease Congenital nephrogenic diabetes insipidus X-linked lymphoproliferative syndrome – Trials in Disease Prolymphocytic leukaemia – Treatment Nephroblastoma – Trials in Disease Bronchopulmonary dysplasia Hyperoxaluria Lysosomal storage disorder – Trials in Disease Mucopolysaccharidosis II Sjogren’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Emtricitabine Indacaterol Acetate Vibosameran Diacerein Azelastine Hydrochloride Sulfasalazine Ifezuntirgene Inilparvovec RUBIDIUM CHLORIDE Pyridoxine Hydrochloride Bp Canagliflozin Sodium Alginate Erythromycin Lactobionate Sunitinib Phleum Pratense Pollen Extract Bi 685509 Vindesine Sulfate Etoricoxib Necvax-Neo1 Avalotcagene Ontaparvovec Deflazacort More therapies…

    Learn about Your Condition

    Leukoencephalopathy Device related infection Corneal dystrophy Osteogenesis imperfecta Henoch-Schonlein purpura Trisomy 21 Osteochondrodysplasia Neck pain Breast angiosarcoma Respiratory tract infection Choroidal dystrophy Uterine leiomyoma Glaucoma Ependymoma malignant Hypersensitivity More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Systemic lupus erythematosus

  • Study on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Idiopathic inflammatory myopathy
    • Systemic scleroderma
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Aldesleukin
    Germany

  • Study on the Effects of Rituximab and Obinutuzumab in Patients with Systemic Lupus Erythematosus (SLE)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Obinutuzumab
    • Rituximab
    The Netherlands

  • Study on the Effects of Belimumab for Patients with Systemic Lupus Erythematosus (SLE)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Belimumab
    The Netherlands

  • Long-term Safety Study of AUTO4 and Rituximab in Patients with Potential Malignancy Treated with Autologous CAR T Cell Therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-Hodgkin’s lymphoma
    • Systemic lupus erythematosus
    • Acute lymphocytic leukaemia
    Investigated Drugs:
    • Auto4
    • Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22
    • Rituximab
    Spain

  • Study on the Safety of MB-CART19.1 for Patients with Active Systemic Lupus Erythematosus, Systemic Sclerosis, or Dermatomyositis/Polymyositis

    Recruiting

    1 1 1
    Investigated Diseases:
    • Idiopathic inflammatory myopathy
    • Systemic scleroderma
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
    Germany

  • Study on the Safety and Effectiveness of CABA-201, Fludarabine Phosphate, and Cyclophosphamide in Patients with Active Systemic Lupus Erythematosus

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Caba-201
    • Fludarabine Phosphate
    • Cyclophosphamide
    France Spain
Previous Page
1 2 3 4 … 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!